MacroGenics Q2 FY26 turns to net income of $19.52 million; revenue more than doubled to $32.83 million
MGNX•Asset sale boosts cash position and extends runway
The company sold its GMP drug-substance manufacturing operations to Bora for a $122.5 million base price, receiving $119.6 million cash at closing.
Pro forma cash and marketable securities totaled $327 million, extending runway guidance through 2028. MacroGenics also said ESMO 2026 data are planned for MGC026 and lorigerlimab.
MacroGenics swings to quarterly profit as revenue more than doubles
MacroGenics swung to GAAP net income of $19.5 million in Q2 2026 from a net loss a year earlier.
Revenue more than doubled to $32.8 million, driven by a $24.5 million Sanofi regulatory milestone tied to U.S. TZIELD approval.
R&D expense edged down to $38.8 million; G&A fell to $7.9 million on lower personnel-related costs.
